Company

Resolution of the USSR Council of Ministers was signed on the construction of an antibiotic plant in Saransk. 63 years later the Biokhimik plant will become part of the Promomed Group. 

Petr Bely and like-minded people established the PROMOMED company.

The first new drug products have been developed and launched: Revocarin and Neosmectin

A new weight loss drug product Reduxin developed by Promomed became available at pharmacies. Within a year it became the top product in this category. 

Promomed opened a modern production site at the plant for manufacturing tablets and capsules

Creation of the in-house biotechnological laboratory – Scientific and Production Engineering Center “Antibiotic”. 

Promomed obtained the conclusion from the Ministry of Industry and Trade of the Russian Federation on the compliance of manufacturing process at Biokhimik  with the requirements of the Good Manufacturing Practice (GMP).

Minister of Health of the Russian Federation Veronika Skvortsova opened a full cycle production of domestic antibiotics of the latest generations at Biokhimik 

Promomed Group opened a laboratory of chemical and pharmaceutical technologies at the Ogarev Mordovia State University as part of cooperation with the Biokhimik plant

Promomed DM LLC successfully issued its first bonds listed on Moscow stock exchange. It became the first Russian pharmaceutical company available for investing.

Innovational production process for tablets and capsules was launched at the Biokhimik manufacturing facility, using fully automated contactless technologies of pharmaceutical manufacturing, ensuring completion of full production cycles without human involvement, according to pre-defined parameters. The production line, with capacity of 1 bln tablets and capsules per year, is equipped with the most up-to-date machinery, enabling the production of multilayer and multicomponent tablets, among other tasks. The manufacturing facility of such class is the only one in Russia and one of the three of such kind in Europe.

The biggest in Russia manufacturing facility for active pharmaceutical ingredients (API) was opened. The event was attended by Vladmir Putin, the President of the Russian Federation, and Denis Manturov, deputy Prime Minister, the minister of trade and commerce of the Russian Federation, in a videoconference format. The manufacturing facility includes 7 production lines, including isolated technologies for the synthesis of the antineoplastic and highly potent drug substance. All kinds of APIs can be manufactured, with the capacity of up to 340 mln tons per year.

Construction of the research and manufacturing complex of Artcellence biotechnological company, of which Promomed is among its key stakeholders, began in the specialized economic area “Technopolis Moscow”.

The Biokhimik manufacturing facility, the core of Promomed’s production capacities was certified according to the Eurasian GMP standards.

23 marketing authorizations received, including Salvisar, Drotaverin, Piracetam, Etamsilat, Ibuprofen, Dioxydin.

Promomed acquired the Biokhimik plant. A new story has begun for the oldest pharmaceutical enterprise.

Marketing authorization obtained for: Ketoprofen, Ketorolac, Sumatriptan, Metformin, Troxerutin

Launch of modernized workshops for the production of tablets, ointments and gels.

The substance for innovative antibiotic Vancomycin has been developed

10 marketing authorizations received, including Ambene Bio, Amikacin, Ofloxacin, Ciprofloxacin

Promomed provided support in opening  new department at the Ogarev Mordovia State University, which will be involved in studies of synthesis of new antibiotics.

Promomed has put into commercial operation its own solution for managing the traceability of goods movement, including product labeling and aggregation.

10 marketing authorizations received, including antibiotics Moxifloxacin, Levofloxacin, Azithromycin, Doripinem, Vancomycin 

The company started its own production of substances by chemical and biological synthesis, sterile drugs in liquid and lyophilised forms

Marketing authorization for 21 new medicinal products received, including Reduxin Forte, Etoricoxib, Ademetionine, Citicoline, Tranexamic acid, Meloxicam and more 

Development and obtaining marketing authorization for Areplivir, a drug recommended by the Russian Ministry of Health for COVID-19  treatment, which saved hundreds of thousands of lives during the 2020-2021 pandemic

Promomed DM is assigned long-term credit rating ruBBB+ with a stable outlook.

Production plant of Promomed Group in Saransk has launched the production of a full cycle of antiviral drugs – an important step towards the national independence of drug supply

10 new medicinal products added to the company's portfolio: Ambene Chondro, Amiodarone, Daptomycin, Lidocaine, Linezolid, Lornia, Tolsitol, Phosphocreatine and more

The Biokhimik manufacturing facility became a partner of the Federal project “Professionality”.

The Promomed group has invested in the Artcellence biotechnological company, the latter to focus on development and full cycle manufacturing of biosimilar products and other innovational medicines for the treatment of cancers and other diseases incurring a high social burden.

The company obtained regulatory approval and provided the healthcare system with Esperavir® — a new medicine becoming available in Russia for the treatment of coronavirus infection, based on molnupiravir, a globally acknowledged compound.

The company obtained regulatory approval for Skaivira®, a product for etiotropic treatment for COVID-19

Medicines manufactured by the Promomed group became part of the new guidelines on prevention and treatment of COVID-19 developed by the Russian Ministry of Health.

The Biokhimik manufacturing facility has increased its number of employees, offering more than 200 new job opportunities in engineering and production.

The Promomed group obtained approval and launched a novel weight loss medication (INN - liraglutide), under the trade name of Enligria.

The Promomed group obtained approvals and launched Quinsenta (INN – semaglutide) and Quilnliro (INN – liraglutide) for the treatment of type 2 diabetes mellitus on the Russian market.

Brainmax, another product by the Promomed group, was awarded with the right to use the registration sign “Made in Russia” issued by the Russian Export Center.

The Artcellence biotechnological company, of which Promomed is among its key stakeholders, obtained residential status in the specialized economic area “Technopolis Moscow”.

The Promomed group won the nomination “For dynamic development” at an award competition held by the Russian Union of Industrialists and Entrepreneurs”.

The Promomed group won the nomination “A technologically advanced project” at an award competition held by the Russian Union of Industrialists and Entrepreneurs”.

Petr Bely, the founder of the Promomed group, was awarded with Pirogov’s order for merits in pharmaceutical manufacturing.

Long-term credit rating of Promomed DM was upgraded to ruA-, with stable prognosis.

The company’s COVID portfolio was updated with the addition of Enoparin, and anticoagulant. This resulted in a comprehensive arsenal of treatments for COVID-19 and its complications: antivirals, antibiotics, anticoagulants and steroids.

Since the beginning of the year 20 new drug approvals, including oncology portfolio.